Omada Health (NASDAQ:OMDA – Free Report) had its target price raised by Needham & Company LLC from $23.00 to $24.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.
A number of other analysts have also recently commented on the stock. The Goldman Sachs Group initiated coverage on shares of Omada Health in a report on Tuesday, July 1st. They set a “buy” rating and a $29.00 target price on the stock. Evercore ISI upped their price target on shares of Omada Health from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. Wall Street Zen upgraded shares of Omada Health to a “hold” rating in a research note on Monday, June 16th. Morgan Stanley initiated coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued an “overweight” rating and a $25.00 price target on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued an “overweight” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.57.
Check Out Our Latest Stock Analysis on Omada Health
Omada Health Stock Down 2.3%
Omada Health (NASDAQ:OMDA – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). The firm had revenue of $61.37 million for the quarter, compared to analysts’ expectations of $55.17 million.
Hedge Funds Weigh In On Omada Health
A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new position in Omada Health in the 2nd quarter worth about $637,000. Teacher Retirement System of Texas purchased a new position in Omada Health in the 2nd quarter worth about $640,000. Emerald Mutual Fund Advisers Trust purchased a new position in Omada Health in the 2nd quarter worth about $2,950,000. Jennison Associates LLC purchased a new position in Omada Health in the 2nd quarter worth about $4,580,000. Finally, Emerald Advisers LLC purchased a new position in Omada Health in the 2nd quarter worth about $5,089,000.
Omada Health Company Profile
Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
See Also
- Five stocks we like better than Omada Health
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Dividend Stocks Raising Payouts—and Backing It Up With Results
- How to Invest in Blue Chip Stocks
- 3 Stocks With Monopoly Power—and Minimal Competition
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.